Navigation Links
Study reveals insights that could aid in therapeutic use of mesenchymal stem cells

BOSTON Mesenchymal stem cells (MSCs), are a newly emerging cellular therapy being tested in approximately 250 clinical trials worldwide to help repair damaged tissues, such as injured heart muscle following a heart attack. The problem is that when culture-expanded MSCs are injected into the circulation, they have trouble gaining access to the inflamed tissuesexactly where their help is needed.

Now, research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital (BWH) reveals new insights into how MSCs "traffic" from the circulation into the tissue, providing important clues that could be used to improve the delivery of this promising therapy. The findings are published in the November issue of the journal Stem Cells.

MSCs have great clinical potential due to their convenient isolation, their lack of significant immunogenicity (allowing for transplantation between individuals), their lack of ethical controversy, their potential to differentiate into tissue-specific cell types, and their ability to promote blood vessel growth. The cells can seek out and repair damaged tissue and treat inflammation resulting from cardiovascular disease, brain and spinal cord injury, cartilage and bone injury, Crohn's disease, and other conditions. Given the systemic nature of many diseases and the desire for minimally invasive therapies, systemic infusion of MSCs holds considerable promise as an effective treatment in many conditions.

But, as senior author Christopher Carman, PhD, explains, in order for MSCs circulating in the bloodstream to have any therapeutic effect, they must first cross the vascular endothelium, the layer of cells that line blood vessels and serve as the primary barrier between the blood and the tissues. Carman and co-corresponding author Jeffrey Karp, PhD, set out to answer the question, "How do MSCs interact with this layer?"

"Our basic approach was to grow isolated endothelial monolayers in the lab in ways that mimic the vascular barrier structure in the body and conduct dynamic high-resolution imaging studies of MSCs interacting with the endothelium under normal or inflamed conditions," explains Carman, an investigator in BIDMC's Center for Vascular Biology Research and Assistant Professor of Medicine at Harvard Medical School (HMS).

Their experiments revealed that, similar to white blood cells that act during an immune response, MSCs use inflammation-specific adhesion molecules called vascular cell adhesion molecule-1 (VCAM-1) to stick to the endothelium at sites of inflammation. "But," says Carman, "whereas white cells very efficiently crawl over the endothelial surface, apparently searching out weak spots to breach and migrate across this barrier, we discovered that MSCs are unable to mediate such crawling and are about 10 times slower to cross the endothelium." And that, he adds, may explain why MSCs are not efficient at entering inflamed tissues.

"This work suggests that the initial phase of the homing cascadecell rollingis the rate limiting step to achieve effective homing for MSCs," says Karp, Co-Director of the Center for Regenerative Therapeutics at BWH, and Associate Professor of Medicine at HMS. (Homing occurs when circulating MSCs target areas of injury in response to signals of cellular damage; cell rolling refers to the way that MSCs "decelerate" on this target tissue.)

"Clinically this would be a good place to focus efforts to enhance MSC homingto improve the ability to roll on inflamed endothelium, since we showed that MSCs can efficiently adhere under static conditions and transmigrate on the endothelium in inflamed tissues," adds Karp, who is also a principal faculty member of the Harvard Stem Cell Institute.

The scientists further discovered that when MSCs do eventually cross the endothelium, they often do so through "membrane blebbing." During this unique process, an MSC uses hydrostatic pressure to create a bulge or bleb in the cell's outer membrane that exerts mechanical force against the endothelium, leading to the initial break in its barrier that initiates transmigration. "We demonstrated that MSCs can transmigrate between endothelial cellscalled paracellular transmigrationand directly through a single endothelial cellcalled transcellular migration," says Karp. "This is an exciting finding as it provides a new axis that potentially can be modulated for developing next-generation MSC therapy." During transcelluar migration, an MSC doesn't actually enter an endothelial cell, but rather forms a pore through which it then migrates.

Interestingly, say the researchers, these findings may also provide insights on how some tumor cells spread or metastasize, as migratory blebbing has been observed in a number of embryonic germ cells and in some tumor cells. "Our finding shows for the first time that blebbing may function in the critical barrier-breaching event of MSC migration through endothelial cells," says Carman. "This suggests that blebs could similarly function in cancer invasiveness."

For now, however, Carman and his colleagues will focus on MSCs. Among their next steps is to verify that the results generated in the lab hold true within the body. "From there, we wish to iterate back and forth between our in vitro and in vivo systems to explore a range of bioengineering approaches that build on the new knowledge from this study to design improved delivery and efficacy of MSC therapeutics," says Carman, adding that as the understanding of the mechanisms of MSC movement grows, researchers' abilities to enhance homing to specific tissues through engineered approaches should help bring MSC therapy closer to the clinic.


Contact: Bonnie Prescott
Beth Israel Deaconess Medical Center

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition has announced ... Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday 2015, a ... including their ability to work and be productive, to do simple daily activities like ...
(Date:12/1/2015)... ... December 02, 2015 , ... ClinicoEconomics and Outcomes Research ... of treatment for osteoporosis ”. , As corresponding author Dr Ankita Modi says ... with osteoporosis. Based on a large US managed care database, women aged 55 ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an ... has filed a discrimination claim against the U.S. Department of Health and Human Services, ... Care Act (ACA) plans are breaking the clause in the law prohibiting the denial ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Paul Vitenas, one of the ... named by MedEsthetics magazine as the Best Single Physician Practice in the nation. Dr. ... elite aesthetic physicians honored by the industry publication. , Dr. Vitenas said he ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... epidemic in the 1980s we have seen vast improvements in scientific research and ... made significant strides, providing increased hope and relief to those affected by HIV/AIDS. ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015   MabVax Therapeutics Holdings, Inc . (OTCQB: ... has filed an Investigational New Drug Application (IND) with ... Company,s lead fully human antibody product HuMab 5B1 as ... to initiate the Phase I clinical trial early in ... The planned Phase I trial will evaluate the ...
(Date:12/1/2015)... FRANCISCO , Dec. 1, 2015  InCarda Therapeutics, ... development and commercialization of therapies for cardiovascular conditions via ... a subsidiary business in Australia . ... trial in Australia in the ... leading investigators and medical centers in Adelaide ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
Breaking Medicine Technology: